Suppr超能文献

前体药物:设计与临床应用

Prodrugs: design and clinical applications.

作者信息

Rautio Jarkko, Kumpulainen Hanna, Heimbach Tycho, Oliyai Reza, Oh Dooman, Järvinen Tomi, Savolainen Jouko

机构信息

Department of Pharmaceutical Chemistry, University of Kuopio, PO Box 1627, FI-70211 Kuopio, Finland.

出版信息

Nat Rev Drug Discov. 2008 Mar;7(3):255-70. doi: 10.1038/nrd2468.

Abstract

Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which can then exert the desired pharmacological effect. In both drug discovery and development, prodrugs have become an established tool for improving physicochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically active agents. About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend. To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.

摘要

前药是药物分子的生物可逆衍生物,它们在体内经历酶促和/或化学转化以释放活性母体药物,然后母体药物可发挥所需的药理作用。在药物研发过程中,前药已成为改善药理活性剂的物理化学、生物药剂学或药代动力学性质的既定工具。全球约5-7%获批的药物可归类为前药,在药物研发早期采用前药策略的趋势日益明显。为了说明前药策略的适用性,本文描述了最适合前药设计的常见官能团,并重点介绍了已上市或正在进行人体试验的前药实例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验